<DOC>
	<DOCNO>NCT01972152</DOCNO>
	<brief_summary>The purpose study demonstrate G-Pen ( TM ) glucagon comparable Lilly Glucagon ( TM ) term safety efficacy , treatment severe hypoglycemia , complication diabetes .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetic ( PK ) Pharmacodynamic ( PD ) Study G-Pen ( TM ) ( Glucagon Injection ) Treat Severe Hypoglycemia</brief_title>
	<detailed_description>Primary objective : To Evaluate Safety Tolerability G-Pen™ ( Glucagon Injection ) 1 mg Secondary objective ( 1 ) : To Evaluate pharmacodynamics ( Efficacy ) G-Pen™ ( Glucagon Injection ) 1 mg Secondary objective ( 2 ) : To compare pharmacokinetics G-Pen™ ( glucagon injection ) 1mg [ test ] administer 0.5 mg 1 mg injection , versus Lilly Glucagon™ ( glucagon injection [ rDNA origin ] ) 1 mg ( reference )</detailed_description>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>1 . Healthy male female subject age 18 60 year age , inclusive , Screening . 2 . Women must nonchildbearing potential define one following : Females &gt; 45 &lt; 60 year age Screening amenorrheic least 2 year Females document hysterectomy and/or bilateral oophorectomy . 3 . Females childbearing potential negative pregnancy test Screening Treatment visit , use one follow form contraception duration participation study ( i.e. , Followup 714 day post last dose ) : Oral contraceptive Injectable progesterone Subdermal implant Spermicidal foam/gel/film/cream/suppository Diaphragm spermicide Copper hormonal contain intrauterine device ( IUD ) Sterile male partner vasectomize &gt; 6 month predosing . 4 . Male subject require use condom one method contraception 2. 3. start Randomization duration study . 5 . Evidence personally sign date informed consent document indicate subject inform pertinent aspect study . 6 . Subjects must willing able comply schedule visit , treatment , laboratory test study procedure . 1 . Recent ( i.e. , within three ( 3 ) month prior Screening ) evidence medical history unstable concurrent disease : documented evidence history clinically significant hematological , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , immunological , clinically significant neurological disease . 2 . Mean triplicate set seat BP reading Screening , confirm 1 set triplicate Screening , deem necessary systolic blood pressure ( SBP ) &lt; 90 &gt; 140 mm Hg , diastolic blood pressure ( DBP ) &lt; 50 &gt; 90 mm Hg . 3 . Cardiovascular event within 6 month prior screen unstable angina , acute coronary syndrome , myocardial infarction , therapeutic coronary procedure ( e.g. , stent placement , Percutaneous Transluminal Coronary Angioplasty ( PTCA ) , Coronary Artery Bypass Grafting ( CABG ) ) , stroke transient ischemic attack . 4 . Clinically significant ECG abnormality . 5 . Study participant pregnant Screening eligible study . 6 . Breast feeding must discontinue subject wish participate study . 7 . Positive test hepatitis B , hepatitis C , HIV find Screening . 8 . Positive urine drug test illicit drug Screening . 9 . Allergies glucagon , glucagonlike product excipients investigational formulation . 10 . Recent ( i.e. , within three ( 3 ) month prior Screening ) administration glucagon . 11 . Any prior cerebrovascular accident major permanent neurological damage aphasia , hemiparesis , dementia . 12 . Peripheral artery disease uncontrolled claudication 13 . Current diagnosis current clinical evidence New York Heart Association classification heart failure . 14 . Subjects follow abnormality clinical laboratory test Screening , confirm single repeat , necessary : Total bilirubin &gt; 1.5x upper limit normal ( ULN ) aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) ≥ 2.5x ULN . Creatinine &gt; 2.5x ULN . 15 . History regular alcohol consumption define alcohol intake quantity exceed 7 drink per week female 14 drink per week male , 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor . 16 . Participation study involve administration investigational drug device within 30 day 5 halflives , whichever longer , screen current study participation current study . 17 . Blood donation approximately 1 pint ( 500 mL ) within 8 week prior Screening . 18 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Hypoglycemia</keyword>
	<keyword>Glucagon</keyword>
</DOC>